Loading patent…
AssigneeAridis Pharmaceuticals
InventorsSatoshi Ohtake, Vu Truong-Le, David Lechuga-Ballesteros, Luisa Yee, Binh Pham, Russell Martin, Atul Saxena
Estimating the term…
A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.
A pharmaceutical formulation that comprises a gallium (III) and citrate dry powder, wherein the powder comprises an anti-microbially effective concentration of gallium (III) and the ratio of citrate to gallium is 2:1, and wherein the mass median aerodynamic diameter (MMAD) of the powder is 3.87 μm to 5.0 μm.
Dependencies are inferred from the claim text.